These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7863359)

  • 1. Forming and reforming the market for third-party purchasing of health care: a German perspective.
    Graf von der Schulenburg JM
    Soc Sci Med; 1994 Nov; 39(10):1473-81. PubMed ID: 7863359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the sickness funds in the Belgian health care market.
    Nonneman W; van Doorslaer E
    Soc Sci Med; 1994 Nov; 39(10):1483-95. PubMed ID: 7863360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. German risk structure compensation: enhancing equity and effectiveness.
    Files A; Murray M
    Inquiry; 1995; 32(3):300-9. PubMed ID: 7591043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk adjustment and risk selection on the sickness fund insurance market in five European countries.
    van de Ven WP; Beck K; Buchner F; Chernichovsky D; Gardiol L; Holly A; Lamers LM; Schokkaert E; Shmueli A; Spycher S; Van de Voorde C; van Vliet RC; Wasem J; Zmora I
    Health Policy; 2003 Jul; 65(1):75-98. PubMed ID: 12818747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Market Concentration in the Statutory Health Insurance of Germany since the Introduction of Free Choice of Sickness Funds].
    Götze R
    Gesundheitswesen; 2016 Nov; 78(11):715-720. PubMed ID: 25760099
    [No Abstract]   [Full Text] [Related]  

  • 6. The German health care system and health care reform.
    Kamke K
    Health Policy; 1998 Feb; 43(2):171-94. PubMed ID: 10177617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The German Central Health Fund-recent developments in health care financing in Germany.
    Göpffarth D; Henke KD
    Health Policy; 2013 Mar; 109(3):246-52. PubMed ID: 23200602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reimbursement and cost containment: a German perspective.
    Breyer F
    Pharmacoeconomics; 2002; 20 Suppl 3():87-94. PubMed ID: 12457429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Price elasticities in the German Statutory Health Insurance market before and after the health care reform of 2009.
    Pendzialek JB; Danner M; Simic D; Stock S
    Health Policy; 2015 May; 119(5):654-63. PubMed ID: 25670009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk adjustment in Switzerland.
    Beck K; Spycher S; Holly A; Gardiol L
    Health Policy; 2003 Jul; 65(1):63-74. PubMed ID: 12818746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition.
    Busse R; Blümel M; Knieps F; Bärnighausen T
    Lancet; 2017 Aug; 390(10097):882-897. PubMed ID: 28684025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supervision in social health insurance: a four country study.
    Maarse H; Paulus A; Kuiper G
    Health Policy; 2005 Mar; 71(3):333-46. PubMed ID: 15694500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reforming the Israeli health system: findings of a 3-year evaluation.
    Gross R; Rosen B; Shirom A
    Health Policy; 2001 Apr; 56(1):1-20. PubMed ID: 11230905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Notes on the planned German health fund model].
    Robra BP; Mayrhofer T
    Gesundheitswesen; 2006 Oct; 68(10):650-2. PubMed ID: 17099827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care über alles: how it works in Germany.
    Rublee DA
    Healthc Financ Manage; 1992 Jan; 46(1):40, 42, 44-7. PubMed ID: 10145559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysing the impact of health-care system change in the EU member states--Germany.
    Wörz M; Busse R
    Health Econ; 2005 Sep; 14(Suppl 1):S133-49. PubMed ID: 16161188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Competition among health insurers from the perspective of a statutory health insurance company].
    Fischer B
    Z Evid Fortbild Qual Gesundhwes; 2009; 103(10):635-8; discussion 643. PubMed ID: 20120192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-adjusted capitation payments: developing a diagnostic cost groups classification for the Dutch situation.
    Lamers LM
    Health Policy; 1998 Jul; 45(1):15-32. PubMed ID: 10183010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-adjusted capitation. The Israeli experience.
    Shmueli A; Chinitz D
    Eur J Public Health; 2001 Jun; 11(2):182-4. PubMed ID: 11420807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Has solidarity survived? A comparative analysis of the effect of social health insurance reform in four European countries.
    Maarse H; Paulus A
    J Health Polit Policy Law; 2003 Aug; 28(4):585-614. PubMed ID: 12956517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.